RECOVER (NOLVA)
$169.00
Ships from Australia Discreet packaging
191 in stock
| Number of Items | Discount |
|---|---|
| 2 | 5% |
| 3 | 10% |
| 4 | 15% |
| 5 | 20% |
RECOVER (NOLVA) – Powerful SERM for Estrogen Control & PCT
RECOVER (NOLVA) is a highly effective Selective Estrogen Receptor Modulator (SERM) often categorized as an anti-estrogen. However, it acts as both an antagonist and agonist, meaning it blocks estrogen in certain areas of the body while mimicking estrogen in others.
This unique dual action makes RECOVER (NOLVA) one of the longest-standing and widely used SERMs for both medicinal applications and anabolic research. While often incorporated into steroid cycles, it is not an anabolic steroid itself—an important distinction for those new to research applications.
Key Benefits of RECOVER (NOLVA)
Anti-Estrogenic Protection – Prevents estrogen from binding to receptors in certain tissues, reducing side effects.Gynecomastia Prevention – Used to protect against estrogen-related breast tissue growth during anabolic research.Post-Cycle Therapy (PCT) Support – Aids in stimulating natural testosterone production after research protocols.Clinically Backed – Extensively studied for hormonal regulation and breast cancer treatment.Non-Steroidal – Often confused as an anabolic compound, RECOVER (NOLVA) is not an anabolic steroid.
Suggested Combinations
- For Comprehensive PCT Support → Stack with RESTORE (CLOM) to optimize hormonal recovery.
- For Estrogen Control in Cycles → Pair with GUARD (ADEX) for superior estrogen suppression.
Dosage Instructions
- Concentration: 40mg/mL
- Volume: 30mL
- Suggested Dosage: 20-40mg (0.5-1mL) per day for 4 weeks. A single bottle provides 30 days of research use.
Storage Instructions
- Store in a cool, dark space such as a cupboard or pantry for best stability.
Ingredients / Purity Report
- Active Ingredient: RECOVER (NOLVA) – (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
- Other Ingredients: Food-grade USP glycol, food-grade ethyl alcohol, and essential oils.
- Purity Analysis: Contact sales@auslabs.email for the latest HPLC purity report.
Medical References
- Burstein, H.J., Temin, S., Anderson, H., Buchholz, T.A., Davidson, N.E., Gelmon, K.E., et al. (2014). Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. Journal of Clinical Oncology, 32(21), 2255–69.
- Dueñas-DÃez, A., Cano Sanchez, J., Calaf i Alsina, J.L. (2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer-Verlag Berlin Heidelberg, p. 52.
- Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., et al. (2007). Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell, 130(5), 811–23.
Disclaimer
No statements made on this page have been evaluated by the Therapeutic Goods Administration (TGA). This product is not intended to diagnose, treat, cure, or prevent any disease or illness. RECOVER (NOLVA) is strictly for research purposes only. Please refer to the TERMS OF USE for more information.
You may also like…
-
PCT SUPPORT STACK
$299.00 -
PCT SUPER STACK
$569.00
